Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

The Colorado Sun: Colorado Mental Health Providers Say They Were “Betrayed” By Medicaid Behavioral health providers stepped up to offer new services to fill a gap, but the promise of higher ...

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...

Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.

Seattle is among several major U.S. cities that are slowly sinking. That’s according to researchers at Virginia Tech, who ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Britain's Virgin Media O2 said it was combining its enterprise unit with business-to-business telecoms provider Daisy Group ...